<SEC-DOCUMENT>0001171843-20-000241.txt : 20200115
<SEC-HEADER>0001171843-20-000241.hdr.sgml : 20200115
<ACCEPTANCE-DATETIME>20200115071512
ACCESSION NUMBER:		0001171843-20-000241
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200115
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200115
DATE AS OF CHANGE:		20200115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		20527304

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_011520.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title></title></head><body><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div></div><p style="text-align: center;"><font style="font-size: 14pt;"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong><br />_____________________</font></p><p style="text-transform: uppercase; text-align: center;"><font style="font-size: 14pt;"><strong>Form 8-K</strong><br />_____________________</font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>CURRENT REPORT</strong></font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></font></p><p align="center"><font style="font-size: 10pt;">Date of Report (Date of earliest event Reported): <!--January 15, 2020-->January 15, 2020 &#160;</font></p><p align="center"><font style="font-size: 12pt;"><strong>BioCryst Pharmaceuticals, Inc.</strong></font><br /><font style="font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;"><strong>Delaware</strong></font></td><td align="center" width="34%"><font style="font-size: 10pt;"><strong>000-23186</strong></font></td><td align="center" width="33%"><font style="font-size: 10pt;"><strong>62-1413174</strong></font></td></tr><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</font></td><td align="center" width="34%"><font style="font-size: 10pt;">(Commission File Number)</font></td><td align="center" width="33%"><font style="font-size: 10pt;">(I.R.S. Employer Identification Number)</font></td></tr></table><p><font style="font-size: 10pt;">&#160;</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="bottom"><td align="center" width="50%"><font style="font-size: 10pt;"><strong>4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703</strong><!----></font></td></tr><tr valign="top"><td align="center" width="50%"><font style="font-size: 10pt;">(Address of Principal Executive Offices) (Zip Code)</font></td></tr></table><p align="center"><font style="font-size: 10pt;"><strong>(919) 859-1302</strong><br />(Registrant's telephone number, including area code)</font></p><p align="center"><font style="font-size: 10pt;"><strong></strong><br />(Former name or former address, if changed since last report)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td colspan="3"><font style="font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br /><br /></font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; margin: 0pt 0px;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><table style="width: 100%; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 40%; border: 1pt solid black; text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of each class</font></td><td style="width: 20%; border-top: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</font></td><td style="width: 40%; border-top: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which registered</font></td></tr><tr style="vertical-align: top;"><td style="border-right: 1pt solid black; border-bottom: 1pt solid black; border-left: 1pt solid black; text-align: center;"><strong><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common Stock</font></strong></td><td style="border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><strong><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BCRX</font></strong></td><td style="border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><strong><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nasdaq Global Select Market</font></strong></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company [&#160;&#160; ]</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160; ]&#160;</p><hr style="page-break-after: always;" noshade="noshade" /><p><font style="font-size: 10pt;">  <strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 8.01. Other Events.</strong></font></p><p><font style="font-size: 10pt;"><p align="left" style="margin-left:0in; margin-right:0in;">On January 15, 2020, BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice president and general manager for the United States.</p>    <p align="left" style="margin-left:0in; margin-right:0in;">On January 15, 2020, the Company issued a news release announcing the matters described in this Item 8.01.&#160; A copy of the news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p></font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></font></p><p><font style="font-size: 10pt;"><div style="text-align: left;" align="center"><table style="border-collapse: collapse; width: 529pt;" border="0" width="705" cellspacing="0" cellpadding="0"><!--StartFragment--><tr style="height: 15.0pt;"><td style="height: 15pt; width: 57pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman', serif; text-align: left; vertical-align: middle; border-top: none; border-right: none; border-bottom: 0.5pt solid windowtext; border-left: none; padding-top: 1px; padding-right: 1px; padding-left: 1px; color: black; font-style: normal; text-decoration: none; border-image: initial; white-space: nowrap;" width="76" height="20">Exhibit No.</td><td style="width: 20pt; padding: 0in 1px; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman', serif; text-align: left; vertical-align: middle; white-space: normal; color: black; font-style: normal; text-decoration: none; border: none;" width="26">&#160;</td><td style="width: 452pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman', serif; text-align: left; vertical-align: middle; border-top: none; border-right: none; border-bottom: 0.5pt solid windowtext; border-left: none; padding-top: 1px; padding-right: 1px; padding-left: 1px; color: black; font-style: normal; text-decoration: none; border-image: initial; white-space: nowrap;" width="603">Description</td></tr><tr style="height: 23.25pt;"><td style="height: 23.25pt; width: 57pt; padding: 0in 1px; font-size: 10pt; font-family: 'Times New Roman', serif; text-align: left; vertical-align: middle; white-space: normal; color: black; font-weight: 400; font-style: normal; text-decoration: none; border: none;" width="76" height="31"><a href="exh_991.htm">99.1</a></td><td style="width: 20pt; padding: 0in 1px; font-size: 10pt; font-family: 'Times New Roman', serif; text-align: left; vertical-align: middle; white-space: normal; color: black; font-weight: 400; font-style: normal; text-decoration: none; border: none;" width="26">&#160;</td><td style="width: 452pt; padding: 0in 1px; font-size: 10pt; font-family: 'Times New Roman', serif; text-align: left; vertical-align: middle; white-space: normal; color: black; font-weight: 400; font-style: normal; text-decoration: none; border: none;" width="603"><a href="exh_991.htm">Press Release dated January 15, 2020 entitled &#8220;BioCryst Strengthens Commercial Rare Disease Leadership.&#8221;</a></td></tr><!--EndFragment--></table></div></font></p><p><font style="font-size: 10pt;"></font></p><p><font style="font-size: 10pt;"></font></p><hr style="page-break-after: always;" noshade="noshade" /><p align="center"><font style="font-size: 10pt;"><strong>SIGNATURE</strong></font></p><p><font style="font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td valign="top" width="49%"><font style="font-size: 10pt;">&#160;</font></td><td style="font-size: 12pt;" colspan="2" valign="top"><font style="font-size: 10pt;"><strong>BioCryst Pharmaceuticals, Inc.</strong></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">Date: January 15, 2020</font></td><td width="2%"><font style="font-size: 10pt;">By:&#160;</font></td><td style="text-decoration: underline;" width="49%"><font style="font-size: 10pt;">/s/ Alane Barnes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Alane Barnes</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Senior Vice President and Chief Legal Officer</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr></table><p /></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>BioCryst Strengthens Commercial Rare Disease Leadership</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">RESEARCH TRIANGLE PARK, N.C., Jan.  15, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice president and general manager for the United States.<br ></p>  <p align="justify">Mr. Gayer joined BioCryst in 2015 as vice president of global strategic marketing. Since July 2019 he has served as interim chief commercial officer, playing a key role in defining the strategy, and building the commercial operations, to support the launch of berotralstat, BioCryst&#8217;s oral kallikrein inhibitor&#160;for hereditary angioedema (HAE).</p>  <p align="justify">Prior to joining BioCryst, Mr. Gayer held several U.S. and global commercial leadership roles in highly competitive rare disease categories at Grifols and Talecris Biotherapeutics from 2007 through 2015. Prior to joining Talecris, he spent six years at GlaxoSmithKline in a range of marketing and sales roles. He received his B.A. from Princeton University and his M.B.A. from the Fuqua School of Business of Duke University.</p>  <p align="justify">&#8220;With Charlie&#8217;s leadership and experience, BioCryst is well-positioned to deliver berotralstat to patients around the world, as we transform into a fully-integrated commercial organization. He has a record of success in rare disease markets and has added valuable strategic insight and creativity to BioCryst over the past four years,&#8221; said Jon Stonehouse, chief executive officer of BioCryst.</p>  <p align="justify">Mr. Hodge joins BioCryst from Array Biopharma, where he helped to build the commercial organization that successfully launched Braftovi<sup>&#174;</sup> and Mektovi<sup>&#174;</sup>, an oral combination used for the treatment of patients with a rare form of melanoma. From 2012 through 2015 he was a sales director at ViroPharma (later Shire), where his teams had responsibility for Cinryze<sup>&#174;</sup> and Firazyr<sup>&#174;</sup>, two pioneering injectable treatments for HAE. He began his career at Pfizer, where he spent nine years in increasingly responsible sales roles. He received his B.S. from Arkansas Tech University and his master&#8217;s from Boston University.</p>  <p align="justify">&#8220;In addition to his proven sales success in HAE, Allen has the recent experience of leading highly successful rare disease launches that built tremendous value for patients and shareholders. Charlie and Allen are attracting exceptional talent to the commercial team as we prepare for an exciting 2020 with multiple regulatory submissions, approvals and launches of berotralstat,&#8221; Stonehouse added.</p>  <p align="justify"><strong>About BioCryst Pharmaceuticals </strong></p>  <p align="justify">BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB<sup>&#174;</sup> (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.</p>  <p align="justify"><strong>Forward-Looking Statements </strong></p>  <p align="justify">This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that developing any HAE product candidate may take longer or may be more expensive than planned; that BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; that the company may not advance human clinical trials with product candidates as expected; that the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold with respect to such product candidate, or withhold market approval for product candidates; that actual financial results may not be consistent with expectations, including that 2019 operating expenses and cash usage may not be within management&#8217;s expected ranges.&#160; Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst&#8217;s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst&#8217;s projections and forward-looking statements.</p>  <p align="justify">BCRXW</p>  <p align="justify"><strong><u>Contact:</u></strong><br >John Bluth<br >+1 919 859 7910<br >jbluth@biocryst.com</p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
